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Abstract
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of
drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/10.
1111/bph.13347/full. This compilation of the major pharmacological targets is divided into eight areas of focus: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, other
ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological
tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related targets. It is a condensed version of
material contemporary to late 2015, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented in the previous Guides to
Receptors & Channels and the Concise Guide to PHARMACOLOGY 2013/14. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification and nomenclature for human
drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent, citable, point-in-time record that will survive
database updates.
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Introduction
In order to allow clarity and consistency in pharmacology, there
is a need for a comprehensive organisation and presentation of
the targets of drugs. This is the philosophy of the IUPHAR/BPS
Guide to PHARMACOLOGY presented on the online free access
database (http://www.guidetopharmacology.org/). This database
is supported by the British Pharmacological Society (BPS), the In-
ternational Union of Basic and Clinical Pharmacology (IUPHAR),
the Wellcome Trust and the University of Edinburgh. Data in-
cluded in the Guide to PHARMACOLOGY are derived in large part
from interactions with the subcommittees of the Nomenclature
Committee of the International Union of Basic and Clinical Phar-
macology (NC-IUPHAR). The Editors of the Concise Guide have
compiled the individual records, in concert with the team of Cu-
rators, drawing on the expert knowledge of these latter subcom-
mittees. The tables allow an indication of the status of the nomen-
clature for the group of targets listed, usually previously published
in Pharmacological Reviews. In the absence of an established sub-
committee, advice from several prominent, independent experts
has generally been obtained to produce an authoritative consen-
sus on nomenclature, which attempts to fit in within the gen-
eral guidelines from NC-IUPHAR. This current edition, the Con-
cise Guide to PHARMACOLOGY 2015/16, is the latest snapshot of
the database in print form, following on from the Concise Guide
to PHARMACOLOGY 2013/14. It contains data drawn from the
online database as a rapid overview of the major pharmacolog-
ical targets. Thus, there are fewer targets presented in the Con-
cise Guide (1761) compared to the online database (2761, as of
August 2015). The priority for inclusion in the Concise Guide is
the presence of quantitative pharmacological data. This means
that often orphan family members are not presented in the Con-
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cise Guide, although structural information is available on the on-
line database. An expansion in the current version of the Concise
Guide is the increased inclusion of approved drugs, which reflects
the aim of the online database to reflect the clinical exploitation
of human molecular targets. Although many of these agents are
much less selective than the tool compounds listed to define in-
dividual targets or groups of targets, we have included them for
the significant interest associated with their use and mechanisms
of action. The emphasis on approved drugs means that the online
database has been expanded to include 8024 ligands (as of August
2015), meaning that additional records now appear in the Con-
cise Guide, primarily in the enzymes section. The organisation of
the data is tabular (where appropriate) with a standardised format,
where possible on a single page, intended to aid understanding
of and comparison within a particular target group. The Concise
Guide is intended as an initial resource, with links to additional
reviews and resources for greater depth and information. Phar-
macological and structural data focus primarily on human gene
products, wherever possible, with links to HGNC gene nomen-
clature and UniProt IDs. In a few cases, where data from human
proteins are limited, data from other species are indicated. Phar-
macological tools listed are prioritised on the basis of selectivity
and availability. That is, agents (agonists, antagonists, inhibitors,
activators, etc.) are included where they are both available (by
donation or from commercial sources, now or in the near future)
AND the most selective. This edition of the Concise Guide is di-
vided into nine sections, which comprise pharmacological targets
of similar structure/function. These are G protein-coupled recep-
tors, ligand-gated ion channels, voltage-gated ion channels, other
ion channels, catalytic receptors, nuclear hormone receptors, en-
zymes, transporters and other protein targets. A new aspect of the
Concise Guide 2015/16 is that each of these sections contains a
complete listing of the families available for inspection on the on-
line database, identifying those families reported in the Concise
Guide by their page numbers. We hope that the Concise Guide
will provide for researchers, teachers and students a state-of-the-
art source of accurate, curated information on the background to
their work that they will use in the Introductions to their Research
Papers or Reviews, or in supporting their teaching and studies.
We recommend that any citations to information in the Concise
Guide are presented in the following format:
Alexander SPH et al. (2015). The Concise Guide to PHARMACOL-
OGY 2015/16: Overview. Br J Pharmacol XXX.
In this overview are listed protein targets of pharmacological inter-
est, which are not G protein-coupled receptors, ligand-gated ion
channels, voltage-gated ion channels, ion channels, nuclear hor-
mone receptors, catalytic receptors, transporters or enzymes.
A dedication
This Edition of the Concise Guide to PHARMACOLOGY is ded-
icated to Tony Harmar (1951-2014). Tony was a friend and
colleague, who was involved with IUPHAR for over 15 years
and worked on the IUPHAR database for over a decade at
Edinburgh, working hard to establish the curators as a team
of highly informed and informative individuals imbued with
Tony’s passion and dogged determination to focus on high-
quality data input, ensuring high-quality data output. With
time and the resources of the BPS and Wellcome Trust, com-
bined with the expertise of the NC-IUPHAR committee mem-
bers mentioned above, Tony established the online database
at http://www.guidetopharmacology.org/ as the exceptional re-
source it is today.
Acknowledgements
We are extremely grateful for the financial contributions from the British Pharmacological Society, the International Union of Basic and Clinical Pharmacology, theWellcome Trust (099156/Z/12/Z]), which
support the website and the University of Edinburgh, who host the guidetopharmacology.org website. We are also tremendously grateful to the long list of collaborators from NC-IUPHAR subcommittees
and beyond, who have assisted in the construction of the Concise Guide to PHARMACOLOGY 2015/16 and the online database www.GuideToPHARMACOLOGY.org
Conflict of interest
The authors state that there are no conflicts of interest to disclose.
c
 2015 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Searchable database: http://www.guidetopharmacology.org/index.jsp Overview 5733
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13347/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Overview. British Journal of Pharmacology (2015) 172, 5729–5743
Other Protein Targets
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5742 Tubulins
– Tumour-associated proteins
– WD repeat-containing proteins
Adiponectin receptors
Other protein targets! Adiponectin receptors
Overview: Adiponectin receptors (provisional nomen-
clature, ENSFM00500000270960) respond to the 30 kDa
complement-related protein hormone adiponectin (also known
as ADIPOQ: adipocyte, C1q and collagen domain-containing
protein; ACRP30, adipose most abundant gene transcript 1;
apM-1; gelatin-binding protein: Q15848) originally cloned from
adipocytes [49]. Although sequence data suggest 7TM domains,
immunological evidence indicates that, contrary to typical 7TM
topology, the carboxyl terminus is extracellular, while the amino
terminus is intracellular [86]. Signalling through these recep-
tors appears to avoid G proteins. Adiponectin receptors appear
rather to stimulate protein phosphorylation via AMP-activated
protein kinase and MAP kinase pathways [86], possibly through
the protein partner APPL1 (adaptor protein, phosphotyrosine in-
teraction, PH domain and leucine zipper containing 1, Q9UKG1
[52]). The adiponectin receptors are a class of proteins (along with
membrane progestin receptors), which contain seven sequences of
aliphatic amino acids reminiscent of GPCRs, but which are struc-
turally and functionally distinct from that class of receptor.
Nomenclature Adipo1 receptor Adipo2 receptor
HGNC, UniProt ADIPOR1, Q96A54 ADIPOR2, Q86V24
Rank order of potency globular adiponectin ( ADIPOQ, Q15848) > adiponectin ( ADIPOQ, Q15848) globular adiponectin ( ADIPOQ, Q15848) = adiponectin ( ADIPOQ, Q15848)
Comments: T-Cadherin (CDH13, P55290) has also been suggested to be a receptor for (hexameric) adiponectin [35].
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Further Reading
Buechler C et al. (2010) Adiponectin receptor binding proteins–recent advances in elucidating
adiponectin signalling pathways. FEBS Lett. 584: 4280-6 [PMID:20875820]
Dalamaga M et al. (2012) The role of adiponectin in cancer: a review of current evidence. Endocr.
Rev. 33: 547-94 [PMID:22547160]
Goldstein BJ et al. (2009) Protective vascular and myocardial effects of adiponectin. Nat Clin Pract
Cardiovasc Med 6: 27-35 [PMID:19029992]
Juhl C et al. (2012) Molecular tools to characterize adiponectin activity. Vitam. Horm. 90: 31-56
[PMID:23017711]
Shetty S et al. (2009) Adiponectin in health and disease: evaluation of adiponectin-targeted drug
development strategies. Trends Pharmacol. Sci. 30: 234-9 [PMID:19359049]
Sun Y et al. (2009) Adiponectin, an unlocking adipocytokine. Cardiovasc Ther 27: 59-75
[PMID:19207481]
Thundyil J et al. (2012) Adiponectin receptor signalling in the brain. Br. J. Pharmacol. 165: 313-27
[PMID:21718299]
Blood coagulation components
Other protein targets! Blood coagulation components
Overview: Coagulation as a patho/physiological process is inter-
preted as a mechanism for reducing excessive blood loss through
the generation of a gel-like clot local to the site of injury. The
process involves the activation, adhesion (see Integrins), degranu-
lation and aggregation of platelets, as well as proteins circulating
in the plasma. The coagulation cascade involves multiple proteins
being converted to more active forms from less active precursors,
typically through proteolysis (see Proteases). Listed here are the
components of the coagulation cascade targetted by agents in cur-
rent clinical usage.
Nomenclature coagulation factor V (proaccelerin, labile factor) coagulation factor VIII, procoagulant component serpin peptidase inhibitor, clade C (antithrombin), member 1
HGNC, UniProt F5, P12259 F8, P00451 SERPINC1, P01008
Selective activators – – heparin (pKd 7.8) [25], fondaparinux (pKd 7.5) [65], dalteparin
[34], danaparoid [15, 58], enoxaparin [17], tinzaparin [19]
Selective antagonists drotrecogin alfa (Inhibition) [40, 41] drotrecogin alfa (Inhibition) [40, 41] –
Further Reading
Astermark J (2015) FVIII inhibitors: pathogenesis and avoidance. Blood 125: 2045-2051 [PMID:25712994]
Non-enzymatic BRD containing proteins
Other protein targets! Bromodomain-containing proteins! Non-enzymatic BRD containing proteins
Overview: bromodomains bind proteins with acetylated lysine residues, such as histones, to regulate gene transcription. Listed herein are examples of bromodomain-containing proteins for which
sufficient pharmacology exists.
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Nomenclature bromodomain adjacent to
zinc finger domain, 2A
bromodomain adjacent to
zinc finger domain, 2B
CREB binding protein polybromo 1 SWI/SNF related, matrix associ-
ated, actin dependent regula-
tor of chromatin, subfamily a,
member 4
HGNC, UniProt BAZ2A, Q9UIF9 BAZ2B, Q9UIF8 CREBBP, Q92793 PBRM1, Q86U86 SMARCA4, P51532
Selective inhibitors GSK2801 (pKd 6.6) [73] GSK2801 (Binding) (pKd
6.9) [73]
I-CBP112 (pKd 6.8) [72] PFI-3 (Binding) (pKd
7.3) [79]
PFI-3 (Binding) (pKd 7.1) [79]
Further Reading
Brand M et al. (2015) Small molecule inhibitors of bromodomain-acetyl-lysine interactions. ACS
Chem Biol 10:22-39 [PMID:25549280]
Filippakopoulos P and Knapp S (2014) Targeting bromodomains: epigenetic readers of lysine acety-
lation. Nat Rev Drug Discov 13: 337-356 [PMID:24751816]
Gallenkamp D et al. (2014) Bromodomains and their pharmacological inhibitors. ChemMedChem 9:
438-464 [PMID:24497428]
Sanchez R et al. (2014) The bromodomain: from epigenome reader to druggable target. Biochim
Biophys Acta 1839: 676-685 [PMID:24686119]
Carrier proteins
Other protein targets! Carrier proteins
Overview: TTR is a homo-tetrameric protein which transports
thyroxine in the plasma and cerebrospinal fluid and retinol (vi-
tamin A) in the plasma. Many disease causing mutations in the
protein have been reported, many of which cause complex dissoci-
ation and protein mis-assembly and deposition of toxic aggregates
amyloid fibril formation [66]. These amyloidogenic mutants are
linked to the development of pathological amyloidoses, including
familial amyloid polyneuropathy (FAP) [1, 13], familial amyloid
cardiomyopathy (FAC) [37], amyloidotic vitreous opacities, carpal
tunnel syndrome [57] and others. In old age, non-mutated TTR
can also form pathological amyloid fibrils [85]. Pharmacological
intervention to reduce or prevent TTR dissociation is being pur-
sued as a theapeutic strategy. To date one small molecule kinetic
stabilising molecule (tafamidis) has been approved for FAP, and is
being evaluated in clinical trials for other TTR amyloidoses.
Nomenclature transthyretin
Common abreviation TTR
HGNC, UniProt TTR, P02766
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CD molecules
Other protein targets! CD molecules
Overview: Cluster of differentiation refers to an attempt
to catalogue systematically a series of over 300 cell-surface
proteins associated with immunotyping. Many members of
the group have identified functions as enzymes (for example,
see CD73 ecto-5’-nucleotidase) or receptors (for example, see
CD41 integrin, alpha 2b subunit). Many CDs are targetted for
therapeutic gain using antibodies for the treatment of prolifera-
tive disorders. A full listing of all the Clusters of Differentiation is
not possible in the Guide to PHARMACOLOGY; listed herein are
selected members of the family targetted for therapeutic gain.
Nomenclature CD2 CD3e molecule,
epsilon (CD3-TCR
complex)
CD20 (membrane-
spanning
4-domains,
subfamily A,
member 1)
CD33 CD52 CD80 CD86 cytotoxic
T-lymphocyte-
associated protein
4 (CD152)
Common
abreviation
– – – – – – – CTLA-4
HGNC, UniProt CD2, P06729 CD3E, P07766 MS4A1, P11836 CD33, P20138 CD52, P31358 CD80, P33681 CD86, P42081 CTLA4, P16410
Selective
inhibitors
– – – – – abatacept [84],
belatacept [16]
abatacept [84],
belatacept [16]
–
Selective
antagonists
alefacept
(Inhibition) [56, 89]
– – – – – – –
Antibodies – catumaxomab
(Binding) [46],
muromonab-CD3
(Binding) [24],
otelixizumab
(Binding) [7]
ofatumumab
(Binding) (pKd 9.9)
[47], rituximab
(Binding) (pKd 8.5)
[78],
ibritumomab tiuxetan
(Binding),
obinutuzumab
(Binding) [2, 68],
tositumomab
(Binding)
lintuzumab (Binding)
(pKd 10) [8],
gemtuzumab ozogamicin
(Binding) [6]
alemtuzumab
(Binding) [22]
– – ipilimumab
(Binding) (pKd
>9) [28],
tremelimumab
(Binding) (pKd
8.9) [30]
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Nomenclature programmed cell death 1 (CD279)
Common abreviation PD-1
HGNC, UniProt PDCD1, Q15116
Antibodies pembrolizumab (Binding) (pKd 10) [9], nivolumab (Binding) (pKd 9.1) [29, 42, 43]
Comments The endogenous ligands for human PD-1 are programmed cell death 1 ligand 1 (PD-L1 aka CD274 ( CD274, Q9NZQ7)) and programmed cell death 1 ligand 2
(PD-L2; PDCD1LG2). These ligands are cell surface peptides, normally involved in immune system regulation. Many types of cancer cells evolve mechanisms to
evade control and elimination by the immune system. Such mechanisms can include inhibition of so-called ’immune checkpoints’, which would normally be
involved in the maintenance of immune homeostasis. An increasingly important area of clinical oncology research is the development of new agents which impede
these evasion techniques, thereby switching immune vigilance back on, and effecting immune destruction of cancer cells. Three molecular targets of checkpoint
inhibitors which are being extensively pursued are cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1), and programmed cell death
ligand 1 (PD-L1). Using antibody-based therapies targeting these pathways, clinical responses have been reported in various tumour types, including melanoma,
renal cell carcinoma [64] and non-small cell lung cancer [39, 51]. pembrolizumab is the first-in-class, anti-PD-1 antibody to be approved by the US FDA, with
ongoing clinical trials for nivolumab (e.g. NCT01673867, NCT01721746) and pidilizumab (NCT02077959, NCT01952769).
Methyllysine reader proteins
Other protein targets! Chromatin-interacting transcriptional repressors!Methyllysine reader proteins
Overview: Methyllysine reader proteins bind to methylated proteins, such as histones, allowing regulation of gene expression.
Nomenclature l(3)mbt-like 3 (Drosophila)
HGNC, UniProt L3MBTL3, Q96JM7
Selective agonists UNC1215 (pKd 6.9) [38]
Further Reading
Liu K et al. (2015) Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA
methylation. Pharmacol Ther 151: 121-140 [PMID:25857453]
Musselman CA et al. (2014) Towards understanding methyllysine readout. Biochim Biophys Acta
1839: 686-693 [PMID:24727128]
Thinnes CC et al. (2014) Targeting histone lysine demethylases - progress, challenges, and the future.
Biochim Biophys Acta 1839: 1416-1432 [PMID:24859458]
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Cytokines and growth factors
Other protein targets! Cytokines and growth factors
Overview: cytokines and growth factors are a group of small proteins released from cells, which act upon the same cell or neighbouring cells, often with a role in immune regulation and/or proliferation.
Listed herein are examples of cytokines and growth factors targetted for therapeutic benefit.
Nomenclature interleukin 1, beta tumor necrosis factor vascular endothelial growth factor A
HGNC, UniProt IL1B, P01584 TNF, P01375 VEGFA, P15692
Antagonists – – aflibercept (Inhibition) [10, 11, 82]
Selective antagonists – etanercept (Inhibition) [18, 23] pegaptanib (Inhibition) [26, 61]
Antibodies gevokizumab (Binding) (pKd 12.5) [36, 53, 71],
canakinumab (Binding) (pKd 10.5) [27], rilonacept
(Binding) [32, 55]
golimumab (Inhibition) (pIC50 10.7) [77], infliximab
(Inhibition) (pKd 8.7) [44], adalimumab (Inhibition)
(pKd >8) [75], certolizumab pegol (Inhibition) [60]
ranibizumab (Inhibition) (pKd 9.8) [3], bevacizumab
(Inhibition) (pIC50 8–8.3) [3]
Fatty acid-binding proteins
Other protein targets! Fatty acid-binding proteins
Overview: Fatty acid-binding proteins are low molecular weight
(100-130 aa) chaperones for long chain fatty acids, fatty acyl CoA
esters, eicosanoids, retinols, retinoic acids and related metabolites
and are usually regarded as being responsible for allowing the oth-
erwise hydrophobic ligands to be mobile in aqueous media. These
binding proteins may perform functions extracellularly (e.g. in
plasma) or transport these agents; to the nucleus to interact with
nuclear receptors (principally PPARs and retinoic acid receptors
[76]) or for interaction with metabolic enzymes. Although se-
quence homology is limited, crystallographic studies suggest con-
served 3D structures across the group of binding proteins.
Nomenclature fatty acid binding protein 1,
liver
fatty acid binding protein 2,
intestinal
fatty acid binding protein 3,
muscle and heart
fatty acid binding protein 4,
adipocyte
fatty acid binding protein 5
(psoriasis-associated)
HGNC, UniProt FABP1, P07148 FABP2, P12104 FABP3, P05413 FABP4, P15090 FABP5, Q01469
Rank order of potency stearic acid, oleic acid >
palmitic acid, linoleic acid >
arachidonic acid,
α-linolenic acid [69]
stearic acid >
palmitic acid,oleic acid >
linoleic acid >
arachidonic acid,
α-linolenic acid [69]
stearic acid, oleic acid,
palmitic acid > linoleic acid,
α-linolenic acid,
arachidonic acid [69]
oleic acid, palmitic acid,
stearic acid, linoleic acid >
α-linolenic acid,
arachidonic acid [69]
–
Comments A broader substrate specificity
than other FABPs, binding two
fatty acids per protein [83].
Crystal structure of the rat
FABP2 [74].
Crystal structure of the human
FABP3 [87].
– Crystal structure of the human
FABP5 [33].
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Nomenclature fatty acid binding protein 6,
ileal
fatty acid binding protein 7,
brain
peripheral myelin protein 2 fatty acid binding protein 9,
testis
fatty acid binding protein 12
HGNC, UniProt FABP6, P51161 FABP7, O15540 PMP2, P02689 FABP9, Q0Z7S8 FABP12, A6NFH5
Comments Able to transport bile acids [88]. Crystal structure of the human
FABP7 [4].
In silico modelling suggests that
FABP8 can bind both fatty acids
and cholesterol [50].
– –
Nomenclature retinol binding protein 1,
cellular
retinol binding protein 2,
cellular
retinol binding protein 3,
interstitial
retinol binding protein 4,
plasma
retinol binding protein 5,
cellular
HGNC, UniProt RBP1, P09455 RBP2, P50120 RBP3, P10745 RBP4, P02753 RBP5, P82980
Rank order of
potency
– stearic acid > palmitic acid, oleic acid,
linoleic acid, α-linolenic acid,
arachidonic acid [70]
– – –
Nomenclature retinol binding protein 7, cellular retinaldehyde binding protein 1 cellular retinoic acid binding protein 1 cellular retinoic acid binding protein 2
HGNC, UniProt RBP7, Q96R05 RLBP1, P12271 CRABP1, P29762 CRABP2, P29373
Rank order of potency – 11-cis-retinal, 11-cis-retinol >
9-cis-retinal, 13-cis-retinal, 13-cis-retinol,
all-trans-retinal, retinol [14]
tretinoin > alitretinoin stearic acid >
palmitic acid, oleic acid, linoleic acid,
α-linolenic acid, arachidonic acid [70]
–
Comments: Although not tested at all FABPs, BMS309403 exhibits high affinity for FABP4 (pIC50 8.8) compared to FABP3 or FABP5 (pIC50 <6.6) [20, 81]. HTS01037 is reported to interfere with FABP4
action [31]. Multiple pseudogenes for the FABPs have been identified in the human genome.
Further Reading
Chmurzy«ska A. (2006) The multigene family of fatty acid-binding proteins (FABPs): function, struc-
ture and polymorphism. J. Appl. Genet. 47: 39-48 [PMID:16424607]
Furuhashi M et al. (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as
drug targets. Nat Rev Drug Discov 7: 489-503 [PMID:18511927]
Kralisch S et al. (2013) Adipocyte fatty acid binding protein: a novel adipokine involved in the
pathogenesis of metabolic and vascular disease? Diabetologia 56: 10-21 [PMID:23052058]
Schroeder F et al. (2008) Role of fatty acid binding proteins and long chain fatty acids in modulating
nuclear receptors and gene transcription. Lipids 43: 1-17 [PMID:17882463]
Storch J et al. (2010) Tissue-specific functions in the fatty acid-binding protein family. J. Biol. Chem.
285: 32679-83 [PMID:20716527]
Yamamoto T et al. (2009) Classification of FABP isoforms and tissues based on quantitative evalua-
tion of transcript levels of these isoforms in various rat tissues. Biotechnol. Lett. 31: 1695-701
[PMID:19565192]
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Sigma receptors
Other protein targets! Sigma receptors
Overview: Although termed ‘receptors’, the evidence for coupling through conventional signalling pathways is lacking. Initially described as a subtype of opioid receptors, there is only a modest
pharmacological overlap and no structural convergence with the G protein-coupled receptors. A wide range of compounds, ranging from psychoactive agents to antihistamines, have been observed to
bind to these sites, which appear to be intracellular.
Nomenclature sigma non-opioid intracellular receptor 1 2
HGNC, UniProt SIGMAR1, Q99720 –
Agonists – PB-28 (pKi 8.3) [5], 1,3-ditolylguanidine (pKi 7.4) [45] – Guinea pig
(Sub)family-selective agonists (RS)-PPCC (pKi 8.8) [67] –
Selective agonists PRE-084 (pIC50 7.4) [80], (+)-SK&F10047 –
Antagonists (-)-pentazocine SM 21 (pIC50 7.2) [48]
Selective antagonists NE-100 (pIC50 8.4) [62], BD-1047 (pIC50 7.4) [54] –
Labelled ligands [3H]pentazocine (Agonist) [3H]-di-o-tolylguanidine (Agonist)
Comments – There is no molecular correlate of the 2 receptor.
Comments: (-)-pentazocine also shows activity at opioid receptors.
Further Reading
Dubrovsky B. (2006) Neurosteroids, neuroactive steroids, and symptoms of affective disorders. Phar-
macol. Biochem. Behav. 84: 644-55 [PMID:16962651]
Guitart X et al. (2004) Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl.)
174: 301-19 [PMID:15197533]
Matsumoto RR et al. (2003) Sigma receptors: potential medications development target for anti-
cocaine agents. Eur. J. Pharmacol. 469: 1-12 [PMID:12782179]
de Medina P et al. (2011) Importance of cholesterol and oxysterols metabolism in the pharmacology
of tamoxifen and other AEBS ligands. Chem. Phys. Lipids 164: 432-7 [PMID:21641337]
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Tubulins
Other protein targets! Tubulins
Overview: Tubulins are a family of intracellular proteins most commonly associated with microtubules, part of the cytoskeleton. They are exploited for therapeutic gain in cancer chemotherapy as
targets for agents derived from a variety of natural products: taxanes, colchicine and vinca alkaloids. These are thought to act primarily through β-tubulin, thereby interfering with the normal processes
of tubulin polymer formation and disassembly.
Nomenclature tubulin, alpha 1a tubulin, alpha 4a tubulin, beta class I tubulin, beta 3 class III tubulin, beta 4B class IVb tubulin, beta 8 class VIII
HGNC, UniProt TUBA1A,
Q71U36
TUBA4A, P68366 TUBB, P07437 TUBB3, Q13509 TUBB4B, P68371 TUBB8, Q3ZCM7
Inhibitors – – vinblastine (pIC50 9), vincristine – – –
(Sub)family-selective inhibitors – – eribulin (pIC50 8.2) [59], paclitaxel
(Mitotic cell cycle arrest in A431
cells) (pEC50 8.1) [63], colchicine
(pIC50 8) [12], cabazitaxel,
docetaxel, ixabepilone
– – –
Further Reading
Kaur R et al. (2014) Recent developments in tubulin polymerization inhibitors: An overview. Eur J
Med Chem 87: 89-124 [PMID:25240869]
Lu Y et al. (2012) An overview of tubulin inhibitors that interact with the colchicine binding site.
Pharm. Res. 29: 2943-71 [PMID:22814904]
Perdiz D et al. (2011) The ins and outs of tubulin acetylation: more than just a post-translational
modification? Cell. Signal. 23: 763-71 [PMID:20940043]
Schappi JM et al. (2014) Tubulin, actin and heterotrimeric G proteins: coordination of signaling and
structure. Biochim. Biophys. Acta 1838: 674-81 [PMID:24071592]
Song Y et al. (2015) Post-translational modifications of tubulin: pathways to functional diversity of
microtubules. Trends Cell Biol. 25: 125-36 [PMID:25468068]
Yu I et al. (2015) Writing and Reading the Tubulin Code. J. Biol. Chem. 290: 17163-72
[PMID:25957412]
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